Siegfried AG

  • Logo
About Siegfried AG

Siegfried is your preferred partner for complete integrated drug substance and drug product services with production capabilities worldwide.  Our professionalism is pivotal for your project throughout the entire life cycle.  Creating and manufacturing formulations is our passion.  Having such a combination of inherited technical know-how and expertise is unique for a supplier of development and manufacturing services.

Drug Substances services include Custom Development and Contract Manufacturing for both API and intermediates, combined with our own product portfolio of API (opiates and other controlled substances) and dossiers with independent patented technologies.

Drug Products clients benefit from a broad base of inherited knowledge in complex oral drug delivery systems including sterile filling, with in-house development, customer development and manufacturing, and a broad portfolio of finished dosage form products.

Improving chemical processes and formulations is our expertise. We work closely with customers to develop and optimize innovative chemical processes adding more benefit and value. Siegfried has 11 sites worldwide spanning both the Eastern and Western Hemispheres with chemical manufacturing multi-purpose cGMP locations in Zofingen, Switzerland; Pennsville, New Jersey, USA; Nantong, China; Minden, Germany; Saint-Vulbas, France; Evionnaz, Switzerland; and drug product manufacturing sites in Zofingen, Switzerland; Malta; Hameln, Germany, Irvine, USA; Barberà del Vallès, Spain and El Masnou, Spain.  

Expect more with Siegfried as your preferred partner.



Certifications
  • CH
  • 2015
    On CPHI since
  • 3
    Certificates
  • 1000 - 4999
    Employees
Company types
Contract Service
Manufacturer/Innovator
Contact info
Meet us at

CPHI Milan 2024

Fiera Milano, Italy
08 Oct 2024 - 10 Oct 2024

Products from Siegfried AG (26)

  • Amlodipine besylate

    Product Amlodipine besylate

    Siegfried Ltd. offers wide range of products and services which includes amlodipine besylate. Therapeutic areas: hypertension. Contact us for more information.
  • Amlodipine mesylate

    Product Amlodipine mesylate

    Siegfried Ltd. offers wide range of products and services which includes amlodipine mesylate. Therapeutic areas: hypertension. Contact us for more information.
  • Aseptic filling

    Product Aseptic filling

    Siegfried Ltd. offers wide range of products and services which includes aseptic filling. It includes suspensions, gels, ointments, etc. Contact us for more information.
  • Candesartan

    Product Candesartan

    Siegfried Ltd. offers wide range of products and services which includes candesartan. Therapeutic areas: hypertension. Contact us for more information.
  • Clinical trial production

    Product Clinical trial production

    Siegfried Ltd. offers wide range of products and services which includes clinical trial production. Contact us for more information.
  • Cmc documentation services

    Product Cmc documentation services

    Siegfried Ltd. offers wide range of products and services which includes cmc documentation services. Contact us for more information.
  • Combination/drug delivery devices

    Product Combination/drug delivery devices

    Siegfried Ltd. offers wide range of products and services which includes combination/drug delivery devices. It includes drug coating implants, drug delivery services, sustained release delivery system. Contact us for more information.
  • Container closures

    Product Container closures

    Siegfried Ltd. offers wide range of products and services which includes container closures. They provide vials, droppers tip bottles, syringes, etc. Contact us for more information.
  • Design for manufacture & scale up

    Product Design for manufacture & scale up

    Siegfried Ltd. offers wide range of products and services which includes design for manufacture & scale up. Contact us for more information.
  • Doxazosin

    Product Doxazosin

    Siegfried Ltd. offers wide range of products and services which includes doxazosin. Therapeutic areas: hypertension. Contact us for more information.
  • Felodipine

    Product Felodipine

    Siegfried Ltd. offers wide range of products and services which includes felodipine. Therapeutic areas: hypertension. Contact us for more information.
  • Final formulation

    Product Final formulation

    Siegfried Ltd. offers wide range of products and services which includes final formulation. Contact us for more information.

Siegfried AG Resources (9)

  • News On track at CPHI Barcelona - The Track Sponsor interviews: Siegfried

    In our packed out content sessions at CPHI Barcelona this year we focus on some of the hottest topics coming up in the pharma industry, with each track sponsored by a leading expert in the field. 
  • Webinar From Lab to Commercial Production -How to Combat Challenges in OSD High Potency Products Development

    Highly Potent APIs are a rapidly growing segment of the global pharmaceutical industry, and they are acquiring a significant relevance into the development space. The importance to understand the challenges around development of High Potency Oral solids formulations, are the key to ensure a right scale-up and launch Risk-based approach: measuring the risk, not the hazard Challenges for High potency products handling. Importance of select the adequate partner Development of secure and scalable process in high containment environment
  • News Siegfried starts to ramp up production after cyber attack

    Hameln plant which provides fill and finish for Pfizer-BioNTech COVID-19 shot should be fully operational within the week, CDMO says
  • Webinar Building a Collaborative Supply Chain for Biological Products: A Roadmap for the Future

    The Covid-19 Pandemic forced us to learn new ways of collaborating and innovating to solve a global crisis - what can we learn and leverage from this experience as we adapt to a 'new normal'?
    Amazing scientific development and break-throughs are evolving faster than ever, with new advanced treatment options for patients being developed at unprecedented speed. All of us involved in manufacturing and supply need to rethink how we collaborate, deliver medicines and learn faster.
    No one company can solve this alone - requiring us to collaborate, innovate and learn in new ways. What does this change really mean for us? Welcome to engage in a discussion, sharing case study data and recent insights in the middle of an industry learning journey.
  • Webinar Process Optimization for Viral Vector Manufacturing

    Though viral vectors are used extensively in cell and gene therapy, the challenges of manufacturing such complex biologics at industrial scale is still a limitation to its broader use.
    Dr. Ayuso will speak about how upstream and downstream process optimization using design of experiments (DOE), a platform approach and end-to-end capabilities can tackle manufacturing challenges and help to expedite drug development.
  • Webinar Keynote Address: Next-Gen Biomanufacturing

    Join Asklepios BioPharmaceutical's former CEO Shelia Ann Mikhail, where she will Set the Scene for the latest innovations and developments affecting the Biomanufacturing Landscape
  • Webinar Overcoming Challenges in Transferring a Sterile Biologics Drug Product to a CDMO

    Ensuring quality and compliance in bio-manufacturing Closing gaps in development data prior to the first GMP production Adjusting manufacturing processes throughout the course of a site-to-site transfer Fulfilling special requirements on container closure systems for biologics Transferring analytical methods for drug products and drug substances
  • Webinar Building a Collaborative Supply Chain for Biological Products: A Roadmap for the Future

    The Covid-19 Pandemic forced us to learn new ways of collaborating and innovating to solve a global crisis - what can we learn and leverage from this experience as we adapt to a new normal? Amazing scientific development and break-throughs are evolving faster than ever, with new advanced treatment options for patients being developed at unprecedented speed. All of us involved in manufacturing and supply need to rethink how we collaborate, deliver medicines and learn faster.
    No one company can solve this alone - requiring us to collaborate, innovate and learn in new ways. What does this change really mean for us? Welcome to engage in a discussion, sharing case study data and recent insights in the middle of an industry learning journey.
  • Webinar "Panel: Strategies for Commercialising Cell and Gene Therapies"

    Manufacturers face unique quality challenges that can hinder progress. In this session, discover quality challenges in Cell and Gene Therapy (CGT) and learn common practices for overcoming them:
    Where are all the approvals? Understanding unique manufacturing challenges for Autologous Cell Therapies How does development by design, quality by design, and Cell Therapy COGs converge in this new space? Creating a Cell Therapy technology roadmap to address challenges and drive speed-to-market